Tumour vascular targeting

By D. Neri, R. Bicknell. Nature Reviews. Cancer, 2005

626 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel (2012, background): “strongly expressed in the cancer neovasculature and stroma but are virtually undetectable in normal adult tissues (6).”
Magnetic nanoparticles in MR imaging and drug delivery. (2008, background): “A relatively large number of angiogenesis markers, which include the αvβ3 integrin, vascular endothelial growth factor (VEGF), cell surface nucleolin, and heparin sulfates, have been identified as potential targets for the delivery diagnostic and therapeutic agents [135,136].”
Antibody targeted drugs as cancer therapeutics (2006, background): “, especially because several tumour endothelial markers are well characterize”
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. (2012, background): “Ligands used to target drugs and/or drug delivery systems to tumor blood vessels include the antibody fragment L19, which uses the EDB domain of the oncofetal protein fibronectin to home to angiogenic vasculature [21,22], and several cyclic and linear derivatives of the oligopeptides RGD and NGR, wh”